Advertisement

Radioimmunotherapy of Colorectal Cancer in Small Volume Disease: Preclinical Evaluation in Comparison to Equitoxic Chemotherapy and Preliminary Results of an Ongoing Phase-I/II Clinical Trial

  • T. M. Behr
  • S. Memtsoudis
  • V. Vougioukas
  • T. Liersch
  • S. Gratz
  • F. Schmidt
  • T. Lorf
  • S. Post
  • B. Wörmann
  • W. Hiddemann
  • B. Ringe
  • W. Becker
Conference paper
Part of the Advances in Pharmacological Sciences book series (APS)

Abstract

The aim of the present study was to compare, in preclinical models, the therapeutic efficacy of radioimmunotherapy in colorectal cancer to equitoxic chemotherapy, as well as to evaluate, in a pilot clinical trial, their efficacy in small volume disease. The data suggest that radioimmunotherapy may be a viable therapeutic option in colorectal cancer patients with limited disease. Myelotoxicity is the only dose-limiting organ toxicity. Although most patients were treated below the maximum tolerated dose, encouraging anti-tumor effects have been observed.

Keywords

Nude Mouse Maximum Tolerate Dose Colorectal Cancer Patient Tumor Cell Inoculation Pilot Clinical Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    DeVita VT, Hellman S, Rosenberg SA (eds.): Cancer — Principles and Practice of Oncology (5th edition). Philadelphia: Lippincott-Raven, 1997.Google Scholar
  2. 2.
    Behr TM, Goldenberg DM, Becker WS: Radioimmunotherapy of solid tumors: a review “Of Mice and Men”. Hybridoma 16: 101–107, 1997.PubMedCrossRefGoogle Scholar
  3. 3.
    Woo DV, Li D, Mattis JA, Steplewski Z: Selective chromosomal damage and cytotoxicity of 125I-labeled monoclonal antibody 17-la in human cancer cells. Cancer Res 49: 2952–2958, 1989.PubMedGoogle Scholar
  4. 4.
    Behr T, Becker W, Bair HJ, Klein M, Stühler CM, Cidlinsky KP, Scheele JR, Wolf FG: Comparison of complete versus fragmented 99mTc-labeled anti-CEA monoclonal antibodies for immunoscintigraphy in colorectal cancer. J Nucl Med 36: 430–441, 1995.PubMedGoogle Scholar
  5. 5.
    Behr TM, Sgouros G, Vougioukas V, Memtsoudis S, Gratz S, Nebendahl K, Schmidberger H, Becker W: Therapeutic efficacy and dose-limiting toxicity of Auger-electron versus beta emitters in radioimmunotherapy with internalizing antibodies: evaluation of 125i-versus 131I-labeled CO17-1A in a colorectal cancer model. Int J Cancer: in press, 1998.Google Scholar
  6. 6.
    Behr TM, Sgouros G, Sharkey RM, Dunn RM, Blumenthal RD, Kolbert K, Juweid ME, Siegel JA, Goldenberg DM: 90Y-Dosimetry in the nude mouse: evaluation of three dosimetry models in relation to the observed biological effects in the radioimmunotherapy of human colon cancer xenografts. Proc 6th Int Radiopharm Dosim Symp Gatlinburg (TN) 1996, in press: 1997.Google Scholar
  7. 7.
    Blumenthal RD, Sharkey RM, Haywood L, Natale AM, Wong GY, Siegel JA, Kennel SJ, Goldenberg DM: Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies. Cancer Res 52: 6036–6044, 1992.PubMedGoogle Scholar
  8. 8.
    Sharkey RM, Natale A, Goldenberg DM, Mattes MJ: Rapid blood clearance of immunoglobulin G2a in nude mice. Cancer Res 51: 3102–3107, 1991.PubMedGoogle Scholar
  9. 9.
    Blumenthal RD, Sharkey RM, Natale AM, Kashi R, Wong G, Goldenberg DM: Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancer xenografts. Cancer Res 54: 142–151, 1994.PubMedGoogle Scholar
  10. 10.
    Behr TM, Sharkey RM, Juweid ME, Dunn RM, Siegel JA, Goldenberg, DM: Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing,cancers with anti-CEA and anti-mucin monoclonal antibodies. J Nucl Med 38: 409–418, 1997.PubMedGoogle Scholar
  11. 11.
    Behr TM, Wulst E, Radetzky S, Blumenthal RD, Dunn RM, Gratz S, Rave-Fränk M, Schmidberger H, Raue F, Becker W: Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type. Cancer Res 57: 5309–5319, 1997.PubMedGoogle Scholar
  12. 12.
    Tschmelitsch J, Barendswaard E, Williams Jr C, Yao TJ, Cohen AM, Old LJ, Welt S: Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil). Cancer Res 57: 2181–2186, 1997.PubMedGoogle Scholar

Copyright information

© Springer Basel AG 1999

Authors and Affiliations

  • T. M. Behr
    • 1
  • S. Memtsoudis
    • 1
  • V. Vougioukas
    • 1
  • T. Liersch
    • 2
  • S. Gratz
    • 1
  • F. Schmidt
    • 3
  • T. Lorf
    • 3
  • S. Post
    • 2
  • B. Wörmann
    • 4
  • W. Hiddemann
    • 4
  • B. Ringe
    • 3
  • W. Becker
    • 1
  1. 1.Department of Nuclear MedicineGeorg-August-University of GöttingenGöttingenGermany
  2. 2.Department of GeneralGeorg-August-University of GöttingenGöttingenGermany
  3. 3.Department of Transplantation SurgeryGeorg-August-University of GöttingenGöttingenGermany
  4. 4.Department of Hematology-OncologyGeorg-August-University of GöttingenGöttingenGermany

Personalised recommendations